Publications by authors named "Travis J Cohoon"

Myoepithelioma of the soft tissue is a rare entity that can mimic myxoma when presenting within the heart. We present a case where cardiopulmonary bypass venous cannula extraction catheter removal of an intracardiac myoepithelioma was attempted with minimal debulking and subsequently required minimally invasive open-heart surgery with cardiopulmonary bypass. ().

View Article and Find Full Text PDF

Background: Phase space is a mechanical systems approach and large-scale data representation of an object in 3-dimensional space. Whether such techniques can be applied to predict left ventricular pressures non-invasively and at the point-of-care is unknown.

Objective: This study prospectively validated a phase space machine-learned approach based on a novel electro-mechanical pulse wave method of data collection through orthogonal voltage gradient (OVG) and photoplethysmography (PPG) for the prediction of elevated left ventricular end diastolic pressure (LVEDP).

View Article and Find Full Text PDF

Introduction: Elevated left ventricular end diastolic pressure (LVEDP) is a consequence of compromised left ventricular compliance and an important measure of myocardial dysfunction. An algorithm was developed to predict elevated LVEDP utilizing electro-mechanical (EM) waveform features. We examined the hierarchical clustering of selected features developed from these EM waveforms in order to identify important patient subgroups and assess their possible prognostic significance.

View Article and Find Full Text PDF

Translesional coronary pressure measures the hemodynamic significance of epicardial coronary artery disease. Angiographic-physiologic mismatching is attributed mainly to imaging limitations. We present a patient with extreme visual-physiologic functional mismatch and a markedly elevated left ventricular end diastolic pressure (LVEDP) as a potential contributory mechanism.

View Article and Find Full Text PDF

The rapid development of digital health devices has enabled patients to engage in their care to an unprecedented degree and holds the possibility of significantly improving the diagnosis, treatment and monitoring of many medical conditions. Combined with the emergence of artificial intelligence algorithms, biometric datasets produced from these digital health devices present new opportunities to create precision-based, personalized approaches for healthcare delivery. For effective implementation of such innovations to patient care, clinicians will require an understanding of the types of datasets produced from digital health technologies; the types of analytic methods including feature selection, convolution neural networking, and deep learning that can be used to analyze digital data; and how the interpretation of these findings are best translated to patient care.

View Article and Find Full Text PDF
Article Synopsis
  • Triple-negative breast cancers (TNBCs) are characterized by the lack of hormone receptors and HER2 amplification, making them diverse and challenging to treat.
  • Researchers discovered that the IκB kinase-related (IKK-related) kinase IKBKE and the JAK/STAT signaling pathway are active in immune-activated TNBCs, working together to promote tumor growth.
  • Treatment with CYT387, a specific inhibitor of IKBKE and JAK signaling, effectively reduced cancer cell proliferation and tumor growth, especially when combined with a MEK inhibitor, highlighting a promising new treatment approach for TNBC.
View Article and Find Full Text PDF

Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) have been discovered in several cancer types and cause the neurometabolic syndrome D2-hydroxyglutaric aciduria (D2HGA). The mutant enzymes exhibit neomorphic activity resulting in production of D2-hydroxyglutaric acid (D-2HG). To study the pathophysiological consequences of the accumulation of D-2HG, we generated transgenic mice with conditionally activated IDH2(R140Q) and IDH2(R172K) alleles.

View Article and Find Full Text PDF
Article Synopsis
  • KRAS, a key player in tumor development, activates additional pathways beyond MAPK and PI3K, which are crucial for tumor maintenance.
  • Researchers found that the kinases TBK1 and IKKε support KRAS-driven tumor growth by regulating the release of cytokines like CCL5 and IL-6.
  • The drug CYT387 effectively inhibits these signaling pathways, leading to reduced tumor growth and enhanced treatment effects when combined with MAPK inhibition in mouse models of lung cancer.
View Article and Find Full Text PDF

Unlabelled: The success in lung cancer therapy with programmed death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between EGF receptor (EGFR) pathway activation and a signature of immunosuppression manifested by upregulation of PD-1, PD-L1, CTL antigen-4 (CTLA-4), and multiple tumor-promoting inflammatory cytokines. We observed decreased CTLs and increased markers of T-cell exhaustion in mouse models of EGFR-driven lung cancer.

View Article and Find Full Text PDF

Purpose: Amplification of MYC is one of the most common genetic alterations in lung cancer, contributing to a myriad of phenotypes associated with growth, invasion, and drug resistance. Murine genetics has established both the centrality of somatic alterations of Kras in lung cancer, as well as the dependency of mutant Kras tumors on MYC function. Unfortunately, drug-like small-molecule inhibitors of KRAS and MYC have yet to be realized.

View Article and Find Full Text PDF

The LKB1/STK11 tumor suppressor encodes a serine/threonine kinase, which coordinates cell growth, polarity, motility, and metabolism. In non-small cell lung carcinoma, LKB1 is somatically inactivated in 25% to 30% of cases, often concurrently with activating KRAS mutations. Here, we used an integrative approach to define novel therapeutic targets in KRAS-driven LKB1-mutant lung cancers.

View Article and Find Full Text PDF

KRAS is the most commonly mutated oncogene, yet no effective targeted therapies exist for KRAS mutant cancers. We developed a pooled shRNA-drug screen strategy to identify genes that, when inhibited, cooperate with MEK inhibitors to effectively treat KRAS mutant cancer cells. The anti-apoptotic BH3 family gene BCL-XL emerged as a top hit through this approach.

View Article and Find Full Text PDF